Top
Main
 
All Outcomes
 
Feedback
Home
c19early.org COVID-19 treatment researchBudesonideBudesonide (more..)
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta
Cannabidiol Meta Molnupiravir Meta
Colchicine Meta
Conv. Plasma Meta
Curcumin Meta Nigella Sativa Meta
Ensovibep Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Peg.. Lambda Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Ivermectin Meta
Lactoferrin Meta

Loading...

Supplementary Data — Budesonide for COVID-19: real-time meta analysis of 12 studies

@CovidAnalysis, September 2023
https://c19early.org/umeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ STOIC Ramakrish.. (RCT) 82% 0.18 [0.04-0.79] hosp./ER 2/73 11/73 Improvement, RR [CI] Treatment Control STOIC Ramakrish.. (RCT) 90% 0.10 [0.01-0.75] hosp./ER 1/70 10/69 STOIC Ramakrish.. (RCT) 67% 0.33 [0.15-0.72] no recov. 7/70 21/69 TOGETHER Reis (DB RCT) -200% 3.00 [0.12-73.5] death 1/738 0/738 CT​1 TOGETHER Reis (DB RCT) 12% 0.88 [0.32-2.40] hosp. 7/738 8/738 CT​1 TOGETHER Reis (DB RCT) 50% 0.50 [0.25-0.92] progression 13/738 27/738 CT​1 Ramlall (ICU) 71% 0.29 [0.11-0.78] death 33 (n) 915 (n) Intubated patients PRINCIPLE Yu (RCT) 39% 0.61 [0.22-1.67] death 6/787 10/799 PRINCIPLE Yu (RCT) 6% 0.94 [0.44-1.98] ventilation 13/776 14/784 PRINCIPLE Yu (RCT) 52% 0.48 [0.23-1.01] ICU 10/771 21/779 PRINCIPLE Yu (RCT) 25% 0.75 [0.55-1.03] death/hosp. 72/787 116/1,069 PRINCIPLE Yu (RCT) 17% 0.83 [0.74-0.93] recov. time 787 (n) 1,069 (n) Al Sulaiman (ICU) 32% 0.68 [0.41-1.13] death 30/64 31/64 ICU patients MP 80%​2 Al Sulaiman (ICU) 47% 0.53 [0.31-0.93] death 25/65 29/65 ICU patients MP 80%​2 Alsultan (RCT) -7% 1.07 [0.42-2.71] death 5/14 7/21 TACTIC Agustí (RCT) -23% 1.23 [0.08-19.0] death 1/40 1/49 TACTIC Agustí (RCT) 39% 0.61 [0.12-3.17] progression 2/40 4/49 Yang -11% 1.11 [0.62-1.97] death 30/125 13/60 Samajdar 58% 0.42 [0.08-2.05] death 2/50 5/52 CT​1 Samajdar 65% 0.35 [0.04-3.22] ventilation 1/50 3/52 CT​1 Samajdar 69% 0.31 [0.09-1.07] hosp. 3/50 10/52 CT​1 Samajdar 29% 0.71 [0.55-0.91] no recov. 50 (n) 52 (n) CT​1 Samajdar 10% 0.90 [0.80-1.02] no recov. 50 (n) 52 (n) CT​1 Lee 33% 0.67 [0.42-1.08] cases 19/1,674 95/5,345 Monserrat .. (PSM) 49% 0.51 [0.28-0.90] death n/a n/a Loucera 22% 0.78 [0.65-0.92] death 1,047 (n) 14,921 (n) Budesonide COVID-19 outcomes c19early.org Sep 2023 1 CT: study uses combined treatment2 MP: multiple medications, percentage budesonide shown Favors budesonide Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit